RDY vs. TAK, ALNY, TEVA, GMAB, RPRX, BMRN, BGNE, VTRS, UTHR, and SRPT
Should you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), BeiGene (BGNE), Viatris (VTRS), United Therapeutics (UTHR), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.
Dr. Reddy's Laboratories (NYSE:RDY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment.
14.0% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Dr. Reddy's Laboratories presently has a consensus price target of $81.00, indicating a potential upside of 13.51%. Takeda Pharmaceutical has a consensus price target of $14.00, indicating a potential upside of 3.93%. Given Dr. Reddy's Laboratories' higher probable upside, equities analysts clearly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.
Dr. Reddy's Laboratories received 217 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 59.25% of users gave Dr. Reddy's Laboratories an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.
Dr. Reddy's Laboratories has a net margin of 19.97% compared to Takeda Pharmaceutical's net margin of 6.18%. Dr. Reddy's Laboratories' return on equity of 21.27% beat Takeda Pharmaceutical's return on equity.
Takeda Pharmaceutical has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Dr. Reddy's Laboratories has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.
Dr. Reddy's Laboratories pays an annual dividend of $0.41 per share and has a dividend yield of 0.6%. Takeda Pharmaceutical pays an annual dividend of $0.26 per share and has a dividend yield of 1.9%. Dr. Reddy's Laboratories pays out 10.2% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 47.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Takeda Pharmaceutical and 3 mentions for Dr. Reddy's Laboratories. Takeda Pharmaceutical's average media sentiment score of 0.69 beat Dr. Reddy's Laboratories' score of 0.53 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.
Summary
Dr. Reddy's Laboratories beats Takeda Pharmaceutical on 12 of the 19 factors compared between the two stocks.
Get Dr. Reddy's Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dr. Reddy's Laboratories Competitors List
Related Companies and Tools
